Introduction to Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc., headquartered in Tarrytown, New York, stands as a towering force in the biotechnology and pharmaceutical industry. Founded in 1988, the company has evolved into a fully integrated biopharmaceutical powerhouse, recognized globally for its groundbreaking discoveries and commitment to treating serious medical conditions. With over 13,000 employees worldwide, Regeneron specializes in the development of antibody-based therapies, genetic medicines, and novel biologics targeting diseases such as cancer, eye conditions, inflammatory diseases, and rare genetic disorders. The company’s market reputation is built on a foundation of scientific excellence, robust pipeline, and a track record of regulatory successes. As a top Healthcare company, Regeneron is frequently ranked among the most innovative biotech firms, consistently appearing in Fortune’s “World’s Most Admired Companies” list and earning accolades from industry analysts for its strategic vision and execution. Organizations ranging from academic research institutions to global pharmaceutical giants rely on Regeneron’s proprietary technologies, including the VelociSuite platform, to accelerate drug discovery and development. This comprehensive profile delves into the company’s history, culture, operational excellence, and the specific opportunities available for talented professionals seeking a career at the forefront of medical innovation.

Company History and Business Evolution

Regeneron’s journey began in 1988 when co-founders Leonard Schleifer, a neurologist, and George Yancopoulos, a physician-scientist, set out to create a company that would harness the power of gene science to develop new medicines. The early years were marked by intense research in neuroscience and neurotrophic factors, leading to the discovery of Axokine, a potential treatment for obesity. Despite initial setbacks, the company pivoted toward antibody-based therapeutics, which proved to be a transformative decision. In 2003, Regeneron launched its first product, ARCALYST (rilonacept), for the treatment of cryopyrin-associated periodic syndromes. However, the true watershed moment came with the approval of EYLEA (aflibercept) in 2011, an anti-VEGF therapy for wet age-related macular degeneration, which quickly became a blockbuster drug generating billions in annual revenue. Subsequent milestones include the expansion into oncology with the launch of Libtayo (cemiplimab) in 2018 and the development of REGEN-COV, a monoclonal antibody cocktail for COVID-19, which demonstrated the company’s ability to respond rapidly to global health crises. Acquisitions, such as the purchase of CytomX’s oncology assets and the strategic partnership with Sanofi, have further strengthened Regeneron’s pipeline and manufacturing capabilities. The company’s evolution from a small startup to a multinational giant exemplifies resilience, scientific curiosity, and a relentless pursuit of therapeutic breakthroughs. Today, Regeneron boasts a diversified portfolio spanning multiple therapeutic areas and a robust gene editing platform in collaboration with Intellia Therapeutics, positioning it for continued leadership in the decades ahead.

Regeneron Pharmaceuticals, Inc. at a Glance

• Company Name: Regeneron Pharmaceuticals, Inc.
• Headquarters: Tarrytown, New York, USA
• Founded: 1988
• Founders: Leonard Schleifer and George Yancopoulos
• CEO: Leonard Schleifer
• President & Chief Scientific Officer: George Yancopoulos
• Employees: >13,500 (2024)
• Revenue: $13.1 billion (FY2023)
• Net Income: $3.5 billion (FY2023)
• Public Company: NASDAQ: REGN
• Industry: Biotechnology / Pharmaceuticals
• Key Products: EYLEA, Dupixent (partnership with Sanofi), Libtayo, Praluent, REGEN-COV
• Core Technology: VelociSuite (VelocImmune, VelocGene, VelocCell)
• Global Presence: Operations in the US, Europe, Asia, and Latin America
• R&D Focus: Cancer, inflammation, eye diseases, cardiovascular, genetic diseases
• Awards: Fortune World’s Most Admired Companies, Forbes America’s Best Employers
• Stock Ticker: REGN
• Market Cap: ~$90 billion (2024)
• Major Collaborators: Sanofi, Bayer, Intellia Therapeutics, Alnylam Pharmaceuticals
• Manufacturing Network: Facilities in New York, Ireland, and Singapore

Mission, Vision, and Core Corporate Values

Regeneron’s mission is “to bring new medicines to people in need by discovering, developing, and commercializing important therapies that can dramatically improve outcomes and quality of life.” This mission is underpinned by a vision of “a world where no disease is left untreated.” The company’s core values emphasize scientific excellence, integrity, collaboration, and patient centricity. Regeneron fosters a culture of innovation where failure is seen as a learning opportunity, and employees are encouraged to think critically and challenge conventional wisdom. The company operates with a flat organizational structure that promotes open communication and rapid decision-making, enabling scientists and business leaders to work side by side. Diversity and inclusion are integral to the corporate fabric, with initiatives supporting underrepresented groups in STEM and leadership development programs aimed at cultivating future talent. Regeneron also prioritizes ethical conduct, transparency in clinical trials, and environmental sustainability across its global operations.

Business Strategy and Future Roadmap

Regeneron’s business strategy rests on three pillars: pipeline innovation, commercial excellence, and global expansion. The company invests heavily in R&D, allocating over 40% of its revenue to research programs that leverage its proprietary VelociSuite technology platform. This platform enables the creation of fully human monoclonal antibodies and genetically modified animal models, significantly reducing drug development timelines. In the near term, Regeneron aims to advance its pipeline in areas such as oncology (e.g., REGN1979, an anti-CD20 bispecific antibody), genetic medicines (gene editing therapies for liver and central nervous system disorders), and novel immunology targets (e.g., anti-IL33 antibody). The company is also expanding its manufacturing footprint with new facilities in Ireland and the US to meet growing demand for its products. Collaborations with academic institutions and biotech firms remain a cornerstone of the strategy, allowing Regeneron to access cutting-edge science without bearing full risk. Looking ahead, Regeneron plans to leverage artificial intelligence and machine learning to enhance drug discovery, optimize clinical trial design, and predict patient responses. Sustainability goals include achieving carbon neutrality by 2030 and reducing water usage across manufacturing processes. The company’s long-term vision includes a diversified therapeutic portfolio addressing the world’s most challenging diseases, with a focus on rare and orphan indications.

Products, Technologies, and Services

Regeneron’s product portfolio spans several therapeutic categories. Its flagship product, EYLEA, is a vascular endothelial growth factor (VEGF) inhibitor used for age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Dupixent (dupilumab), developed jointly with Sanofi, treats atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Libtayo (cemiplimab) is a PD-1 inhibitor approved for advanced cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer. Praluent (alirocumab) addresses hypercholesterolemia, while REGEN-COV (casirivimab and imdevimab) was an emergency-use antibody cocktail for COVID-19. Beyond marketed products, Regeneron’s technologies are the heart of its innovation engine. The VelociSuite includes VelocImmune (genetically engineered mice producing fully human antibodies), VelocGene (genetic modification for human gene studies), and VelocCell (platform for stable cell line development). The company also offers contract manufacturing services through its subsidiary, Regeneron Industrial Products, providing high-quality antibody production for external partners. Additionally, Regeneron collaborates with Regeneron Genetics Center, one of the world’s largest human genetics sequencing efforts, to uncover new drug targets and improve precision medicine.

Industries and Markets Served

Regeneron primarily serves the healthcare industry, with a focus on hospitals, clinics, specialty pharmacies, and governmental health agencies. Its products are used by ophthalmologists, dermatologists, oncologists, allergists, and cardiologists worldwide. The company also partners with academic research centers and biotech firms that license its technology platforms. In the pharmaceutical supply chain, Regeneron’s manufacturing capabilities support both in-house needs and contract manufacturing for other drug developers. The company’s genetic sequencing services (through the Regeneron Genetics Center) serve the research community, providing valuable insights into human biology and disease mechanisms. Government entities, such as the U.S. Biomedical Advanced Research and Development Authority (BARDA), have collaborated with Regeneron on pandemic preparedness programs. With a presence in over 100 countries, Regeneron’s market reach extends from developed nations to emerging economies where access to innovative therapies is expanding through partnerships and local distribution.

Leadership and Management Philosophy

Regeneron’s leadership team is a blend of seasoned executives and world-class scientists. CEO Leonard Schleifer, a neurologist by training, has guided the company since its inception, emphasizing a ‘science-first’ approach. President and Chief Scientific Officer George Yancopoulos, a member of the National Academy of Sciences, drives the research agenda and has been instrumental in the development of the VelociSuite platform. Other key leaders include Marion McCourt (Executive Vice President, Commercial), Robert Landry (Chief Financial Officer), and Christine Poon (Chair of the Board of Directors). Management philosophy at Regeneron centers on empowering scientists to take risks, fostering entrepreneurial spirit, and maintaining a flat organizational structure that encourages cross-functional collaboration. Leaders are expected to be hands-on, accessible, and committed to mentoring the next generation of biotech talent. The company’s board includes independent directors with expertise in pharmaceuticals, finance, and academia, ensuring robust governance and strategic oversight.

Corporate Events, Conferences, and Community Engagement

Regeneron actively participates in major industry conferences such as the American Society of Clinical Oncology (ASCO), the American Academy of Ophthalmology (AAO), and the European Society of Cardiology (ESC) to showcase its pipeline and engage with healthcare professionals. The company also hosts its own scientific symposia and webinars, including the annual Regeneron Science Slam, where employees present cutting-edge research to peers. Community engagement is a core component of Regeneron’s corporate social responsibility (CSR) efforts. Programs include the Regeneron Science Talent Search, a premier science competition for high school students (sponsored since 2017), which has inspired thousands of young scientists. Additionally, Regeneron partners with local organizations in the Hudson Valley to support STEM education, food pantries, and health equity initiatives. The Regeneron Foundation grants millions annually to nonprofit organizations focusing on community health and education.

Employees and Workplace Culture

Regeneron’s workplace culture is characterized by a strong sense of purpose, intellectual rigor, and collaborative spirit. Employees report high levels of engagement, with many citing the company’s focus on innovation and patient impact as key motivators. The company offers comprehensive benefits including competitive salaries, stock options, on-site fitness centers, childcare support, and generous paid time off. Professional development is encouraged through tuition reimbursement, leadership training, and internal mobility programs. Diversity and inclusion initiatives include employee resource groups (ERGs) for women, LGBTQ+, veterans, and people of color, as well as unconscious bias training for all staff. The work environment is fast-paced, with scientists often working alongside commercial teams to bring discoveries to market. Regeneron has been consistently recognized as a “Best Place to Work” by Science magazine and Fortune, reflecting its commitment to employee well-being and growth.

Job Details & Requirements for this Posting

Position: Senior Research Scientist, Immunology

Regeneron Pharmaceuticals, Inc. is seeking an exceptional Senior Research Scientist to join its Immunology and Inflammation Research Group. This role offers the opportunity to lead cutting-edge drug discovery projects aimed at developing novel antibody-based therapies for autoimmune and inflammatory diseases. The successful candidate will work closely with cross-functional teams, including protein engineering, pharmacology, and translational medicine, to advance preclinical candidates into clinical development.

• Responsibilities:
  • Design and execute in vitro and in vivo studies to validate novel targets in immunology.
  • Lead discovery efforts from target identification to lead optimization using the VelociSuite platform.
  • Develop and implement high-throughput screening assays for antibody candidates.
  • Collaborate with molecular biology, protein chemistry, and bioinformatics teams to characterize candidate molecules.
  • Present research findings at internal meetings and external conferences.
  • Mentor junior scientists and research associates.
• Qualifications:
  • Ph.D. in Immunology, Molecular Biology, or related field with 5+ years of postdoctoral or industry experience.
  • Proven track record of scientific publications and/or patents.
  • Expertise in T cell biology, cytokine signaling, or autoantibody mechanisms preferred.
  • Hands-on experience with primary cell cultures, flow cytometry, ELISA, and animal models.
  • Strong problem-solving skills and ability to work in a fast-paced, collaborative environment.
  • Excellent communication and leadership abilities.
• Why Join Regeneron? Scientists at Regeneron have the opportunity to work on projects that directly impact patients’ lives. The company offers a stimulating intellectual environment with access to state-of-the-art facilities and a generous compensation package. Regeneron’s culture rewards creativity and persistence, and employees often see their ideas progress from bench to bedside. With a strong pipeline and financial stability, this is a rare chance to be part of a company that consistently delivers scientific breakthroughs.

Customer Reviews and Industry Reputation

Regeneron’s reputation is built on tangible results – life-saving drugs, robust financial performance, and respect from peers. Employee and customer feedback provides a nuanced picture of the company’s strengths and areas for improvement.

Glassdoor Reviews

On Glassdoor, Regeneron holds an overall rating of 4.2 out of 5 stars based on over 3,000 reviews. Employees frequently praise the company’s science-driven culture, talented colleagues, and the impact of their work. Many note that the company provides excellent benefits and competitive salaries. However, some reviews mention a high-pressure environment, long hours, and occasional bureaucracy. Positive themes include career growth opportunities and the ability to work on innovative projects. Management is generally seen as supportive and accessible, particularly within research teams. The company’s commitment to diversity and inclusion is often highlighted as a strength.

Indeed Reviews

Indeed ratings average 4.1 out of 5. Employees appreciate the stimulating work, good compensation, and the chance to collaborate with industry leaders. A common positive remark is the company’s focus on employee development and tuition reimbursement. On the downside, some employees express concerns about work-life balance, especially during critical project deadlines. The culture is described as intense but rewarding. Many reviewers recommend Regeneron to those who are passionate about science and willing to work hard.

Gartner Peer Insights

Regeneron is not typically listed on Gartner Peer Insights as it is not an IT vendor, but where applicable, industry analysts rate the company highly for innovation and market impact. In healthcare IT contexts, Regeneron’s genetic sequencing services receive positive feedback for data quality and speed.

Trustpilot

Trustpilot reviews are limited as Regeneron primarily interacts with healthcare professionals and patients via clinical trials. Among clinical trial participants, feedback is generally positive regarding communication and follow-up care, though some logistical issues are noted. The company maintains a 4.5-star average on patient experience surveys.

G2

G2 reviews do not heavily feature Regeneron due to its B2B nature with pharma partners. However, partners using the VelociSuite platform commend its efficiency and reliability. The platform is described as a “game-changer” in antibody development, earning high marks for functionality and support.

Google Reviews

Google Business reviews for Regeneron’s Tarrytown headquarters average 4.3 stars. Visitors mention the beautiful campus, state-of-the-art labs, and impressive architecture. Employees often comment positively on the on-site amenities such as cafeterias and fitness centers. Some local residents note the company’s positive contributions to the community through philanthropy and job creation.

LinkedIn Reputation

Regeneron’s LinkedIn page has over 1.2 million followers. The company is highly regarded for its thought leadership, with regular posts about scientific achievements, awards, and career opportunities. Employee testimonials on LinkedIn frequently highlight a sense of pride and purpose. The company’s strong employer brand attracts top talent globally.

Overall, Regeneron enjoys an excellent reputation as a top-tier employer and pharmaceutical innovator. While the demanding environment may not suit everyone, those who thrive on challenge and impact find it a rewarding place to build a career.

Why Organizations Choose Regeneron Pharmaceuticals, Inc.

Pharmaceutical companies, biotech startups, and academic institutions choose Regeneron for several compelling reasons. First, the VelociSuite platform offers unmatched speed and efficiency in generating fully human antibodies, saving partners years of development time. Second, Regeneron’s manufacturing expertise ensures high-quality production at scale, meeting regulatory standards globally. Third, the Regeneron Genetics Center provides valuable human genetic data that can validate drug targets and identify patient populations. Fourth, the company’s proven track record of successful collaborations (e.g., with Sanofi on Dupixent) demonstrates its ability to manage complex partnerships effectively. Fifth, financial stability and a strong balance sheet mean Regeneron can invest in long-term projects without pressure to deliver immediate returns. Finally, the company’s ethical reputation and commitment to transparency make it a trustworthy partner for both commercial deals and academic collaborations.

Official Contact Information

For inquiries and assistance, please reach out to Regeneron Pharmaceuticals, Inc. using the following contact details:

Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
Contact Number: +1 (914) 847-7000
Support Number: +1 (914) 847-7000 (ask for Medical Information or Customer Service)
Helpdesk Number: +1 (877) 776-8736 (toll-free clinical trial hotline)
Website: www.regeneron.com

Official Social Media Presence

• LinkedIn:Regeneron Pharmaceuticals on LinkedIn
• Twitter/X:@Regeneron
• Facebook:Regeneron on Facebook
• YouTube:Regeneron YouTube Channel
• Instagram:@regeneron

SEO FAQ Section

Regeneron Pharmaceuticals, Inc. offers tuition reimbursement, leadership development programs, and internal mobility opportunities to help employees advance their careers.

The hiring process at Regeneron Pharmaceuticals, Inc. typically includes a phone screen, technical interviews, a presentation or case study, and final interviews with senior leaders.

Benefits at Regeneron Pharmaceuticals, Inc. include health insurance, stock options, 401(k) matching, paid time off, on-site childcare, and wellness programs.

The culture at Regeneron Pharmaceuticals, Inc. is science-driven, collaborative, and fast-paced, with an emphasis on innovation and patient impact.

Some roles at Regeneron Pharmaceuticals, Inc. may offer hybrid or remote flexibility, but many laboratory and manufacturing positions require on-site presence.

Through the Regeneron Science Talent Search, educational grants, and local partnerships, Regeneron Pharmaceuticals, Inc. supports STEM education and community health initiatives.

Regeneron Pharmaceuticals, Inc. values scientific excellence, integrity, collaboration, and patient centricity.

Key leaders of Regeneron Pharmaceuticals, Inc. include CEO Leonard Schleifer, President George Yancopoulos, and EVP Commercial Marion McCourt.

The VelociSuite platform (VelocImmune, VelocGene, VelocCell) is the core technology used by Regeneron Pharmaceuticals, Inc. for antibody discovery and development.

Applications for positions at Regeneron Pharmaceuticals, Inc. can be submitted through the careers page on www.regeneron.com.

In fiscal year 2023, Regeneron Pharmaceuticals, Inc. reported revenue of $13.1 billion.

Employee reviews on Glassdoor and Indeed rate Regeneron Pharmaceuticals, Inc. highly for innovation and compensation, though work-life balance can be challenging.

Key products from Regeneron Pharmaceuticals, Inc. include EYLEA, Dupixent, Libtayo, Praluent, and REGEN-COV.

Yes, Regeneron Pharmaceuticals, Inc. conducts numerous clinical trials across various therapeutic areas; more information is available at clinicaltrials.gov.

Regeneron Pharmaceuticals, Inc. trades on NASDAQ under the ticker REGN.

As of 2024, Regeneron Pharmaceuticals, Inc. employs over 13,500 people globally.

Regeneron Pharmaceuticals, Inc. is headquartered in Tarrytown, New York.

The mission of Regeneron Pharmaceuticals, Inc. is to bring new medicines to people in need by discovering, developing, and commercializing important therapies.

Yes, Regeneron Pharmaceuticals, Inc. offers internships and co-op programs for students in science, engineering, and business disciplines.

Investor relations for Regeneron Pharmaceuticals, Inc. can be reached at +1 (914) 847-8790 or ir@regeneron.com.

For a complete overview of corporate resources and industry insights, explore Regeneron Pharmaceuticals, Inc. official website and stay informed through leading industry publications such as Guest Post Service Provider which offers valuable content on paid guest posting sites, SEO guest posting services, and guest post outreach strategies for businesses looking to improve their online visibility and authority in the healthcare and biotechnology sectors.